Journal
HEMATOLOGICAL ONCOLOGY
Volume 27, Issue 1, Pages 23-30Publisher
WILEY
DOI: 10.1002/hon.875
Keywords
multiple myeloma; cell line; enzastaurin; gene expression profiling; molecular pathway
Categories
Funding
- Associazione Italiana Ricerea Sol Cancro (AIRC)
- Associazione Italiana Leucemie (AIL), Milano
- MIUR [FIRB 2006061851-004]
- Fondazione Italiana Ricerca sul Cancro (FIRC)
- Fondazione Cassa di Risparmio di Modena
Ask authors/readers for more resources
The protein kinase C (PKC) pathway has been shown to play a role in the regulation of cell proliferation in several haematological malignancies, including multiple myeloma (MM). Recent data have shown that a PKC inhibitor, enzastaurin, has antiproliferative and proapoptotic activity in a large panel of human myeloma cell lines (HMCLs). In order to further characterise the effect of enzastaurin in MM, we performed gene expression profiling of enzastaurin-treated KMS-26 cell line. We identified 62 upregulated and 32 downregulated genes that are mainly involved in cellular adhesion (CXCL12, CXCR4), apoptosis (CTSB, TRAF5, BCL2L1), cell proliferation (IGF1, GADD45A, BCMA (B-cell maturation antigen), CDC20), transcription regulation (MYC, MX11, IRF4), immune and defence responses. Subsequent validation by Western blotting of selected genes in four enzastaurin-treated HMCLs was consistent with our microarray analysis. Our data indicate that enzastaurin may affect important processes involved in the proliferation and survival of malignant plasma cells as well as in their interactions with the bone marrow microenvironment and provide a preclinical rationale for the potential role of this drug in the treatment of MM. Copyright (C) 2008 John Wiley & Sons, Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available